Formulation Effects on the Thermomechanical Properties and Permeability of Free Films and Coating Films: Characterization of Cellulose Acetate Films - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Formulation Effects on the Thermomechanical Properties and Permeability of Free Films and Coating Films: Characterization of Cellulose Acetate Films
The authors investigate the effects of a polyethylene glycol plasticizer and water on cellulose acetate film properties.


Pharmaceutical Technology
Volume 33, Issue 3, pp. 88-100

Conclusion

Understanding formulation factor effects on free-film and coating-film properties would provide guidelines for selecting a formulation in the early design stage of developing semipermeable membranes. The results from this study demonstrated that formulation factors such as plasticizer and water level, signifantly affect free-film properties and coating performance. With increasing plasticizer level, the mechanical strength of the free films decreased and the permeability of the films increased. With the interaction of plasticizer and water, the effects on the properties of free films were even greater. Although there were no significant differences in free film properties between CA-398-10NF-EP and CA-398-10TG, the permeability of coating films increased with decreasing acetyl content in CA polymers. The acetyl content over a range of about 1.0% affected permeability of coating films at some degree and the effects were largely dependent on the formulation. With higher plasticizer level and water level in the formulation, the acetyl content only slightly affected the permeability of the coating film. This study demonstrates that it is important to design a robust formulation to reduce the variability of a finished product. It should be realized that besides formulation factors, processing conditions are key controls in ensuring product quality and keeping the release profile of a product in a desirable range.

Jinghua Yuan* is a principal technical service representative, Doug Dunn is a senior lab technician, Nancy M. Clipse is a research analyst, and Ray J. Newton, Jr. is a senior research associate, all at Formulation Products Lab, Pharmaceutical Formulations Group, Eastman Chemical Company, Kingsport, TN 37662, tel. 423.229.8627, fax 423.224.0414,

*To whom all correspondence should be addressed.

Submitted: May 6, 2008. Accepted: Oct. 1, 2008.




What would you do differently? Submit your comments about this paper in the space below.

References

1. N. Ramakrishna and B. Mishra, "Plasticizer Effect and Comparative Evaluation of Cellulose Acetate and Ethylcellulose-HPMC Combination Coatings as Semipermeable Membranes for Oral Osmotic Pumps of Naproxen Sodium," Drug Dev. Ind. Pharm. 28 (4), 403–412 (2002).

2. G. Deepak and P. Kilambi, "The Fabrication and Evaluation of the Formulation Variables of a Controlled-Porosity Osmotic Drug Delivery System," Pharm. Technol. 27 (9), 58–68 (2003).

3. S.N. Makhija and P.R. Vavia, "Controlled Porosity Osmotic Pump-Based Controlled Release Systems of Pseuoephedrine I. Cellulose Acetate as a Semipermeable Membrane," J. Controlled Release 89, 5–18 (2003).

4. T. Guyonnet, C. Brossard, and D. Lefort des Ylouses, "Prolongation of Release of Theophylline Derivatives from Cellulose Acetate-based Tablets," J. Pharmacie de Belgiue 45 (2), 111–119 (1990).

5. O.Y. Abdallah, N.A. Boraie, and V.F. Naggar, "Preparation and Evaluation of Metformin Hydrochloride Controlled-Release Tablets," S.T.P. Pharma 4 (1), 15–20 (1988).

6. M. Corbo et al. "Taste Masking Coating Composition Based on Methacrylate polymer and Cellulose Ester," World Patent No. 2001080826 (2001).

7. M.R. Hoy and E.J. Roche, "Taste Mask Coatings for Preparation of Chewable Pharmaceutical Tablets," US Patent No. 5489436 (1996).

8. E.J. Roche, "Taste Masking and Sustained-Release Coatings Containing Cellulose Derivatives for Pharmaceuticals," Europe Patent No. 459695 (1991).

9. R.K. Verma, D.M. Krishna, and S. Gard, "Formulation Aspects in the Development of Osmotically Controlled Oral Drug Delivery Systems," J. Controlled Release 79, 7–27 (2002).

10. G. Santus and R.W. Baker, "Osmotic Drug Delivery: A Review of the Patent Literature," J. Controlled Release 35, 1–21 (1995).

11. A.M. Kaushal and S. Garg, "An Update on Osmotic Drug Delivery Patents," Pharm. Technol. 27 (8), 38–97 (2003).

12. J. Yuan, P.P. Shang, and S.H. Wu, "Effects of Polyethylene Glycol on Morphology, Thermomechanical Properties, and Water Vapor Permeability of Cellulose Acetate-Free Films," Pharm. Technol. 25 (10), 62–74 (2001).

13. M.M. Meier et al., "Poly(caprolactone triol) as Plasticizer Agent for Cellulose Acetate Films: Influence of the Preparation Procedure and Plasticizer Content on the Physicochemical Properties," Poly. Adv. Technol. 15 (10), 593–600 (2004).

14. M.M. Meier, L.A. Kanis, and V. Soldi, "Characterization and Drug-permeation Profiles of Microporous and Dense Cellulose Acetate Membranes: Influence of Plasticizer and Pore Forming Agent," Int. J. Pharma. 278, 99–110 (2004).

15. J. Yuan and S.H. Wu, "Sustained-Release Tablets via Direct Compression: A Feasibility Study Using Cellulose Acetate and Cellulose Acetate Butyrate," Pharm. Technol. 24 (10), 92–106 (2000).

16. J. Yuan and J. Zhu, "Investigation of the Opaqueness in Cellulose Acetate 398-10NF Free Films: Water Effects," Eastman Technical Report TR-2005-04061 (2005).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here